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Background: Immediate-release hydrocortisone granules in capsules for opening in 
paediatric appropriate doses have recently been licensed for children with adrenal 
insufficiency. This study evaluated the bioavailability of hydrocortisone granules 
administered as sprinkles onto soft food and yoghurt compared to direct administration to 
the back of the tongue. 
Methods: Randomised, three-period crossover study in 18 dexamethasone-suppressed 
healthy men. In each period the fasted participants received hydrocortisone granules 5mg 
either directly to the back of the tongue, or sprinkled onto soft food (applesauce), or 
yoghurt, followed by 240mL of water. Serum cortisol was measured by LC-MS/MS.  
Results: The cortisol geometric mean Cmax and AUC for direct administration, sprinkles 
onto yoghurt, and sprinkles onto soft food were: Cmax 428, 426, 427 nmol/L & AUC0-inf 
859, 886, 844 h*nmol/L, & AUC0-t 853, 882, 838 h*nmol/L respectively. The 90% 
confidence intervals (CI) for the ratios of Cmax, AUC0-inf & AUC0-t for administration 
with soft food or yoghurt to direct administration were well within the bioequivalent 
range, 80-125%. Median Tmax was similar between methods of administration: 0.63h 
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administered directly, 0.75h on soft food and 0.75h on yoghurt. No adverse events 
occurred during the study.  
Conclusions: Hydrocortisone granules administered as sprinkles onto soft food or 
yoghurt but not mixed with are bioequivalent to those administered directly to the back of 
the tongue. Carers, parents or patients may choose to administer hydrocortisone granules 
either directly or sprinkled onto soft food or yoghurt.  
Introduction 
Hydrocortisone is the standard treatment for children with adrenal insufficiency who 
need life-long glucocorticoid hormone replacement (1,2). Congenital adrenal hyperplasia 
is the commonest cause of adrenal insufficiency in children and hydrocortisone 
replacement therapy needs to be initiated at diagnosis in the neonate to avoid death due to 
an adrenal crisis. Hydrocortisone doses are calculated according to body surface area and 
require careful adjustment as children grow to prevent under- or over-treatment. The total 
daily dose is usually 8-15mg/m2 divided in 3-4 administrations with the highest level in 
the morning and doses as low as 0.5mg may be needed to appropriately titrate treatment 
(1-5).  
Currently, children are medicated with compounded tablets prepared by pharmacists 
or carers to achieve paediatric appropriate doses (3). However, studies of compounding 
hydrocortisone reported that up to 25% of batches from pharmacies and 50% by parents 
were out of specification leading to clinically evident under- or over- treatment (6-8). 
Immediate-release hydrocortisone granules in paediatric-appropriate doses of 0.5, 1.0, 2.0 
and 5.0mg have been shown to be well tolerated, easy to administer and to provide 
appropriate cortisol levels in neonates, infants and children with adrenal insufficiency (9). 
They have been designed for children with taste masking to cover the bitter taste of 
hydrocortisone. Administration is by opening the capsule and placing the granules onto a 
spoon or directly onto the child’s tongue (4). The granules have been recently approved 
in the European Union for replacement therapy of adrenal insufficiency in infants, 
children and adolescents, from birth to < 18 years old.  
Co-administration or sprinkling of medications onto food is a commonly used 
practice that provides flexibility and ease of administration for caregivers, particularly of 
young children or children with difficulty swallowing medication (10-12). Sprinkling 
medication onto food could alter its pharmacokinetic characteristics and it is not known if 
co-administration of hydrocortisone granules with food affects its bioavailability. This 
clinical study was performed in dexamethasone-suppressed healthy men to investigate if 
hydrocortisone granules administered sprinkled onto soft food or yoghurt are 
bioequivalent to hydrocortisone granules administered directly to the back of the tongue. 
Methods 
Study population:  
The target sample size was 18 participants. Between June 2017 and July 2017 19 
participants were enrolled. All participants signed an informed consent form and satisfied 
the inclusion and exclusion criteria. One participant withdrew for personal reasons after 
the second treatment period and was replaced. Serum cortisol concentration values from 
the 18 participants that completed all three treatment periods were included in the 
AD
VA
N
CE
 A
RT
IC
LE
:
JO
UR
NA
L 
O
F 
TH
E 
EN
D
O
CR
IN
E 
SO
CI
ET
Y
J
E
S
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/je
s
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
2
1
0
/js
.2
0
1
8
-0
0
3
8
0
/5
3
6
4
7
4
3
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 1
0
 A
p
ril 2
0
1
9
A
D
V
A
N
C
E
 A
R
T
IC
L
E
Journal of the Endocrine Society; Copyright 2019  DOI: 10.1210/js.2018-00380 
 
 
3
pharmacokinetic  analysis and safety and tolerability data from all 19 participants were 
collected and analysed (13). 
The inclusion criteria were: healthy men aged 18-45 years with no significant medical 
history and a satisfactory baseline physical examination, body mass index (BMI) 18-
30kg/m2, normal baseline safety tests (biochemistry, haematology, electrocardiography, 
vital signs, urine analysis), negative urine drug screen, negative viral serology for HIV, 
Hepatitis B and C and use of effective contraception. The exclusion criteria were: use of 
concomitant medications other than acetaminophen within 14 days prior to dosing, 
vaccination within the previous month, any significant medical history including history 
of any gastrointestinal disorder likely to affect drug absorption, history of infections such 
as current or past tuberculosis, systemic fungal or viral infection and acute bacterial 
infection, sensitivity or contraindication to hydrocortisone or dexamethasone and/or any 
of the ingredients contained in soft food or yoghurt, clinically significant history of drug 
or alcohol abuse, positive alcohol screen prior to dosing, participation in another clinical 
trial or blood donation or transfusion ≥450mL within the previous 3 months, smoking 
within 6 months prior to the study, inability to communicate well with the Investigator 
and shift work. 
Study design 
Open label, randomised, single-dose, single-centre, three-period crossover study in 
dexamethasone-suppressed healthy men to determine the bioavailability of three methods 
of administration of hydrocortisone granules (Alkindi® Diurnal Ltd, UK): 1. 
Hydrocortisone granules administered directly to the back of the tongue; 2. 
Hydrocortisone granules sprinkled onto 5mL soft food (applesauce) and swallowed 
within 3 minutes of preparation; 3. Hydrocortisone granules sprinkled onto 5mL yoghurt 
and swallowed within 3 minutes of preparation. All doses were followed by 240 mL of 
water. Primary endpoints were the pharmacokinetic parameters: Cmax (peak cortisol 
concentration), AUC0-t (area under the curve from the time of administration to the final 
time-point of serum cortisol measurement at 12h), AUC0-inf (area under the curve from 
the time of administration projected to infinity) of hydrocortisone granules 5mg 
administered as sprinkles onto soft food and yoghurt compared to hydrocortisone 
granules 5mg administered as dry granules to the back of the tongue. Secondary 
endpoints were Tmax (time to peak cortisol concentration), safety and tolerability. The 
study design was based on the European Medicines Agency and the United States Food 
and Drug Administration guidelines for the design, conduct and evaluation of 
bioavailability and bioequivalence studies and complied with the ethical standards laid by 
the Declaration of Helsinki and regulatory bodies (13-17). The study was reviewed and 
approved by the Wales Research Ethics Committee (reference number: 17/WA/0114). 
Clinical Trials Authorisation was obtained from the Medicines and Healthcare 
Regulatory Agency prior to the start of the study in accordance with Part 3, Regulation 12 
of the United Kingdom (UK) Statutory Instrument. 
The study was performed at Simbec Research Ltd. All participants underwent 
successful screening and eligibility checks. They were admitted to the research facility on 
the afternoon of the first day (Day -1) and were discharged on the evening of the second 
day (Day 0) of each of the three treatment periods.  Participants fasted from 22:00h on 
Day -1 to 12:00h on Day 0 and received three doses of dexamethasone 1mg with 240mL 
water at 22:00h on Day -1, 06:00h and 12:00h on Day 0 for suppression of their 
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endogenous cortisol production.  On Day 0 of each treatment period 5mg hydrocortisone 
granules were administered at 08:00h by one of the three administration methods. The 
sequence of administration methods for each participant was determined by a 
randomisation code generated by SAS® software version 9.3 (SAS Institute Inc., Cary, 
NC, USA). For each dosing one 5mg capsule was opened, the contents either poured out 
onto a spoon or sprinkled onto soft food or yoghurt, and the capsule inspected for residual 
granules. Participants remained seated upright for 4h after dosing. There was a 7 day 
washout between treatment periods which is longer than 5 elimination half-lives (the 
half-life of hydrocortisone is approximately 100min) (13). Post-study assessments were 
performed 7 days after the last dose of hydrocortisone granules. Safety and tolerability 
assessments (adverse events, laboratory safety, vital signs and 12-lead 
electrocardiography) were recorded throughout the study. 
Sample collection and analysis 
Three blood samples were taken 5 minutes apart starting at 0.5h pre-dose to monitor 
cortisol suppression. Further blood was collected pre-dose and up to 12h post dosing on 
Day 0 for quantification of serum cortisol concentration (a total of 20 samples for each 
individual and treatment period with post-dose samples at 0 (-2mins), 0.25, 0.5, 0.75, 1, 
1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 11, 12 hours). The blood samples were processed and 
kept at -20°C and analysed for serum cortisol concentration by liquid chromatography 
tandem mass spectrometry (LC-MS/MS) at Seirian Laboratories, Simbec Research Ltd, 
Cardiff, UK with assay performance data as previously reported (4). 
Pharmacokinetic parameters 
All participants received dexamethasone for suppression of endogenous cortisol levels to 
<1.8µg/dL (<50nmol/L). The mean of three samples taken 5 minutes apart 30 minutes 
pre-dose confirmed suppression and this mean determined the individual endogenous 
baseline serum cortisol. All serum cortisol concentrations thereafter were corrected for 
endogenous baseline levels by subtraction. Any negative baseline adjusted values or 
original concentrations below the limit of quantification were set to zero. The 
pharmacokinetic parameters were calculated following baseline cortisol correction and 
therefore reflect the concentrations achieved by the administration of hydrocortisone 
granules and not endogenous cortisol production (13). The pharmacokinetic parameters 
Cmax, Tmax, AUC0-t, AUC0-inf, λz (elimination rate constant), t1/2 (terminal half-life), CL/F 
(clearance), and Vz/F (apparent volume of distribution), were determined from the 
individual baseline adjusted serum cortisol concentration-time curve using WinNonlin 
Phoenix 6.3 (Certara L.P., St Louis, USA). The actual time of blood sampling was used 
in the calculation of the derived pharmacokinetic parameters.  
Statistical analysis 
Statistical analysis was performed using SAS® software version 9.3 (SAS Institute Inc., 
Cary, NC, USA). For the comparative pharmacokinetic analysis the reference 
administration method was hydrocortisone granules placed directly to the back of the 
tongue and the test administration methods were hydrocortisone granules sprinkled onto 
soft food or yoghurt. Following logarithmic transformation Cmax, AUC0-t and AUC0-inf 
values were subjected to an analysis of variance (ANOVA) including fixed effects for 
sequence, period, treatment and subject nested within sequence. Point estimates and 90% 
two-sided confidence intervals (CI) for the difference between administration methods 
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were obtained using the residual mean square error obtained from the ANOVA model 
and back-transformed to give the CI for the ratio on the original scale (13). The 
administration methods were confirmed to be bioequivalent if the 90% CI of the ratio of 
the test to the reference administration method was within the 80 to 125% range (13). 
Tmax was compared between treatments using separate Wilcoxon Signed-Rank tests at the 
two-sided 5% significance level to test the differences and Hodges-Lehmann estimates of 
the median difference between treatments and corresponding 95% CIs were calculated.  
Results 
Participants and demographics 
Nineteen male participants were randomised and received at least one dose of 
hydrocortisone granules and were eligible for the safety population. Of these, 
one participant withdrew from the study for personal reasons and was replaced. Eighteen 
participants completed the three sequences of this study and were eligible for the 
pharmacokinetic analysis population.   
Mean age (standard deviation sd, range) for the 19 participants who enrolled into the 
study was 31.4 years (8.71, 21 - 44) and mean BMI (sd, range) was 25.96 (2.75, 20.7 - 
29.7). All participants had adequate baseline cortisol suppression with mean pre-dose 
serum cortisol concentrations <1.8µg/dL (<50nmol/L) at each of the three treatment days 
(Day 0) prior to administration of hydrocortisone granules. Overall median baseline 
cortisol for each administration method (direct/ yoghurt/ soft food) (range) was 15.3 
(10.6, 72.4)/ 15.9 (12.5-26.6)/ 14.6 (9.85-81.8). 
Pharmacokinetic analysis  
Following a single 5mg dose of hydrocortisone granules the mean serum cortisol 
concentration over time curve was plotted for each of the three administration methods, 
to assess the rate and extent of absorption. Figure 1 shows the mean and the SD of the 
serum cortisol concentration-time curves adjusted for baseline cortisol for administration 
as dry granules, sprinkles onto soft food, and sprinkles onto yoghurt. The curves were 
very similar between the 3 treatments; there was an initial rapid increase in cortisol 
concentration as expected for an immediate release formulation followed by a gradual 
decline.  
Pharmacokinetic parameters were calculated from the baseline adjusted serum 
cortisol concentration for each administration method and are shown in Table 1. For 
direct administration, administration onto yoghurt, administration onto soft food the 
maximum cortisol concentration Cmax nmol/L (geometric mean) was 428, 426, 427; 
AUC0-t (nmol*h/L) was 853, 882, 838; AUC0-inf (nmol*h/L) was 859, 886, 844. There 
was no statistical difference in Cmax or AUC between methods of administration. Tmax 
(median h, range) for dry granules was (0.625, 0.5-1.25), sprinkles onto soft food (0.75, 
0.25-1.25), sprinkles onto yoghurt (0.75, 0.25-1.5) with no relevant difference between 
methods of administration. 
Comparative bioavailability  
The ratios of the geometric least square means of the pharmacokinetic parameters Cmax, 
AUC0-t, and AUC0-inf for the test (soft food or yoghurt) to the reference (dry granules) 
administration methods were calculated to compare the bioavailability between the 
administration methods. The 90% CI of the ratio for Cmax, AUC0-t, and AUC0-inf were 
well within the 80-125% limits which confirmed that 5mg hydrocortisone granules 
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administered as sprinkles onto soft food or yoghurt is bioequivalent to 5mg administered 
directly as dry granules (Table 2). Soft food to direct administration ratios and 90% CI 
were: Cmax 99.68 (93.98-105.72), AUC0-t 98.24 (94.42-102.21), AUC0-inf 98.21 (94.24-
102.36). Yoghurt to direct administration ratios and 90% CI were: Cmax 99.43 (94.33-
104.80), AUC0-t 103.33 (94.80-112.62), AUC0-inf 103.07 (94.55-112.35).  
Safety and tolerability 
Hydrocortisone granules were safe and well tolerated. There were no adverse events and 
no tolerability issues. Safety laboratory tests (biochemistry, haematology, urine analysis), 
vital signs, and 12-lead electrocardiography parameters were satisfactory at baseline and 
showed no relevant changes over time. There were no relevant physical examination 
findings during the study. All treatment periods exhibited similar safety profile and drug 
tolerability. 
Discussion 
These data show that hydrocortisone granules sprinkled onto soft food and yoghurt are 
bioequivalent to granules administered directly to the back of the tongue in 
dexamethasone-suppressed healthy men. Test-to-reference ratios of the pharmacokinetic 
parameters Cmax, AUC0-t, and AUC0-inf were well within the 80-125% limits required to 
confirm bioequivalence. The peak and total cortisol exposure from hydrocortisone 
granules measured as Cmax and AUC was the same for the three administration methods 
and there was no relevant difference in the rate of absorption measured by Tmax. In this 
short study, hydrocortisone granules were safe and well tolerated, which confirms 
previous findings (4,9). 
Administration of a medication mixed with food is a drug manipulation and could 
affect the absorption of the active ingredient; for example, due to exposure to different 
pH (18). The medicines regulatory agencies in the US and Europe, the FDA and EMA 
respectively, recommend that any such manipulation of drug administration should be 
studied and verified ‘with respect to its potential impact on efficacy and safety’ which 
may include bioavailability studies to confirm if medications sprinkled onto food have 
the same bioavailability as direct administration (18,19). In accordance with this advice 
several studies have assessed the bioequivalence of sprinkles versus the intact form of the 
medication in children and adults (20-25). This study was designed to compare the 
bioavailability of sprinkling the hydrocortisone granules onto food compared to the 
approved use as dry granules to the back of the tongue and confirmed that sprinkling 
hydrocortisone granules onto food does not change its pharmacokinetics. Mixing or 
stirring of hydrocortisone granules with food is not recommended and was not assessed 
due to hydrocortisone granules having a taste-masking layer added to neutralise the bitter 
taste of hydrocortisone which could dissolve if granules are stirred into food. The results 
on direct administration of dry granules in this study mirror previous findings by 
Whitaker et al who tested the pharmacokinetics of single administration of 
hydrocortisone granules in varying doses (0.5, 2.0, 5.0 and 10mg) in 16 dexamethasone-
suppressed healthy adult men (4). The dose tested in our study (5mg) is part of the dose 
range used to treat adrenal insufficiency both in paediatric and adult patients (4,26). In 
the paediatric population the pharmacokinetics of hydrocortisone granules have been 
studied in twenty-four young children with adrenal insufficiency (1month to 6 years old) 
with results comparable to the healthy adult men (9). The palatability of hydrocortisone 
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7
granules was assessed in healthy men who found that the taste was neutral (neither good 
nor bad) 4. 
Administering medications to children can be challenging and many children report 
problems swallowing solid and liquid medicines in the absence of underlying 
neurological disease (27). Compounding of medications to administer as powder and 
mixing medication with food, juice, and sweeteners is a common approach that parents 
and paediatric nurses take to improve compliance especially when there are problems 
swallowing or bitter tasting medications (10,12,28,29) and joint administration of 
medicines with food or drink is an effective strategy to ensure swallowing in children 
(11). Liquid formulations are favoured by young children and contain sweeteners to mask 
any bitter taste.  However, such hydrocortisone suspensions are not licensed, the 
hydrocortisone content may be inconsistent leading to treatment failures (30) and may 
contain sucrose that can have adverse effects on teeth with long-term use (31). Food is 
chewed to <2mm (32) therefore sprinkling beads of smaller size onto food should not 
cause problems swallowing. Furthermore, sprinkling of medication may have advantages 
in improving adherence and facilitate caregiving of patients with swallowing difficulties 
and this approach has been explored in children and elderly patients with potential 
swallowing and adherence difficulties such as in Alzheimer’s disease, attention-deficit 
hyperactivity disorder, and epilepsy (21,22,24,25). 
Dosing errors are common in young children and cause 20% of all medication errors 
in acute neonatal care (33). This is due to the lack of paediatric-appropriate dosage and 
the common use of unlicensed, ‘off-label’ and/or compounded medicines that don’t have 
appropriate labelling, safety or dosing data (33,34). In children adverse drug reactions are 
more common with unlicensed medications (35) and international initiatives have tried to 
address these issues and proposed approaches to improve availability of paediatric-
appropriate formulations and treatment outcomes (29,36). For children with adrenal 
insufficiency compounding hydrocortisone from adult tablets and splitting of adult tablets 
provides much needed flexibility in dosing however recent studies show significant 
inaccuracy in the content of active ingredient leading to clinically significant 
consequences including Cushing’s syndrome (6-8).  
The FDA defines yoghurt products as having a pH of up to 4.6 (37) . The pH of fresh 
plain yoghurt is around 4.3-4.6 and this decreases rapidly with storage time to 4.0-4.2 
(38-40). The pH of different yoghurt products vary within these ranges and is affected by 
the time since production, the initial dairy culture used, addition of fruit or fruit puree and 
the type of fruit added (38). The addition of sweeteners only slightly reduces pH (41) 
(range of pH 3.94-3.98 vs 4.09-3.94). For comparison, the pH of applesauce is lower than 
yoghurt and is between 3.1-3.6. Since the pharmacokinetic analysis in our study showed 
bioequivalence between sprinkles on yoghurt and applesauce we believe that any 
commercial yoghurt product with a pH in the above ranges could be used as a vehicle for 
the sprinkling of hydrocortisone granules.  
The strengths of the study lie in the 3-period crossover design that ensures same 
within-participant control and thus less variability of the data obtained. A double- blind 
design was not required as the primary objective of the study was to compare the 
bioavailability of hydrocortisone granules administered via 3 different methods. The 
pharmacokinetic parameters investigated were objective, and the sequence of 
administration methods was randomly allocated for each individual therefore the open 
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8
label design conferred minimal risk of introducing bias into the study. Further strengths 
of this study are the accurate measurement of cortisol with LC-MS/MS and the complete 
suppression of endogenous cortisol levels in all participants ensuring that cortisol 
measured was the result of treatment and not endogenous production. The study 
population was healthy young men and this can be a potential limitation as 
hydrocortisone granules are designed for the paediatric population; however, the 
absorption of hydrocortisone granules was previously studied in twenty-four young 
children and the results were comparable to the adult population (9). Children may have 
differences in physiology and pharmacokinetics but clinical studies are performed in 
children only under exceptional circumstances and this approach is considered adequate 
by regulatory agencies (13,15,17).  Dexamethasone has been reported in vivo and in vitro 
to induce CYP3A4 of which hydrocortisone is a substrate (42-44). It is possible that 
dexamethasone could alter the pharmacokinetics of hydrocortisone but as each limb of 
the trial was treated in the same way this shouldn’t affect the comparative bioavailability 
under different modes of administration. 
In conclusion it has been demonstrated that hydrocortisone granules can be 
administered either directly or sprinkled onto soft food (applesauce) or yoghurt which, 
when consumed within 3 minutes, did not result in any significant or clinically relevant 
change of overall drug exposure and rate of absorption. Based on the data shown patients 
have the flexibility of multiple administration methods and prescribers can safely 
recommend sprinkled administration of hydrocortisone granules. Carers and children may 
welcome the flexibility of different options for administering hydrocortisone to young 
children on multiple-time daily dosing and it would be interesting to see if this flexibility 
improves adherence to treatment, disease management and clinical outcomes. 
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Figure 1: Mean adjusted serum cortisol concentration and standard deviation over time 
after administration of hydrocortisone granules in 18 fasted, dexamethasone-suppressed 
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healthy men. The serum cortisol concentrations for each participant were corrected for 
endogenous baseline cortisol by subtraction of the mean pre-dose value. 
 Table 1: Pharmacokinetic parameters calculated from baseline adjusted serum cortisol 
following a dose of 5mg hydrocortisone granules administered by three methods  
  Statistic Direct administration Soft food Yoghurt 
Cmax  (nmol/L) Geometric Mean SD 428 427 426 
82 78 88 
AUC0-t    (nmol/L*h) Geometric Mean SD 853  838 882  
203 198 161 
AUC0-inf   (nmol/L*h) Geometric Mean SD 859 844 886 
204 197 162 
Tmax   (h) Median Range 0.63  0.75  0.75  
0.5, 1.25 0.25, 1.25 0.25, 1.5 
λz (1/h) Geometric Mean SD 0.48  0.53  0.55  
0.46 0.24 0.09 
t1/2 (h) Geometric Mean SD 1.4 1.3  1.3  
0.6 0.4 0.2 
sd: standard deviation, cv: coefficient of variation, Geom: geometric mean, Cmax: maximum serum 
cortisol concentration after administration, Tmax: time to Cmax, AUC0-t: area under the serum cortisol 
concentration time curve from administration to the end of the sampling at 12h, AUC0-inf: area under the 
serum cortisol concentration time curve from administration extrapolated to infinite time, λz: terminal rate 
constant, t1/2: serum cortisol concentration half-life 
Table 2: Bioequivalence comparison between the reference administration method (direct 
administration of dry hydrocortisone granules to the back of the tongue) and the test 
administration methods (hydrocortisone granules sprinkled onto yoghurt and sprinkled 
onto soft food) 
 Granules sprinkled onto soft food to direct 
administration of dry granules 
Granules sprinkled onto yoghurt to direct 
administration of dry granules 
 Geometric LSmean 
ratio 90% CI 
Geometric LSmean 
ratio 90% CI 
Cmax (nmol/L) 99.68 93.98-105.72 99.43 94.33-104.80 
AUC0-t (nmol/L*h) 98.24 94.42-102.21 103.33 94.80-112.62 
AUC0-inf (nmol/L*h) 98.21 94.24-102.36 103.07 94.55-112.35 
Cmax: maximum serum cortisol concentration after administration, Tmax: time to Cmax, AUC0-t: area 
under the serum cortisol concentration time curve from administration to the end of the sampling at 12h, 
AUC0-inf: area under the serum cortisol concentration time curve from administration extrapolated to 
infinite time. 
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